These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 37461426)

  • 21. Strengthening the COVID-19 pandemic response, global leadership, and international cooperation through global health diplomacy.
    Javed S; Chattu VK
    Health Promot Perspect; 2020; 10(4):300-305. PubMed ID: 33312925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. South Africa and India push for COVID-19 patents ban.
    Usher AD
    Lancet; 2020 Dec; 396(10265):1790-1791. PubMed ID: 33278923
    [No Abstract]   [Full Text] [Related]  

  • 23. Modelling the spread of SARS-CoV-2 pandemic - Impact of lockdowns & interventions.
    Agrawal M; Kanitkar M; Vidyasagar M
    Indian J Med Res; 2021 Jan & Feb; 153(1 & 2):175-181. PubMed ID: 33146155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recessions and Health: The Long-Term Health Consequences of Responses to the Coronavirus.
    Banks J; Karjalainen H; Propper C
    Fisc Stud; 2020 Jun; 41(2):337-344. PubMed ID: 32836539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three waves of the COVID-19 pandemic.
    Fisayo T; Tsukagoshi S
    Postgrad Med J; 2021 May; 97(1147):332. PubMed ID: 32817567
    [No Abstract]   [Full Text] [Related]  

  • 26. Finding equipoise: CEPI revises its equitable access policy.
    Huneycutt B; Lurie N; Rotenberg S; Wilder R; Hatchett R
    Vaccine; 2020 Feb; 38(9):2144-2148. PubMed ID: 32005536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers.
    Chandrasekharan S; Amin T; Kim J; Furrer E; Matterson AC; Schwalbe N; Nguyen A
    Vaccine; 2015 Nov; 33(46):6366-70. PubMed ID: 26368398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19 and Global Distributive Justice: 'Health Diplomacy' of India and South Africa for the TRIPS waiver.
    Singh B; Chattu VK; Kaur J; Mol R; Gauttam P; Singh B
    J Asian Afr Stud; 2023 Aug; 58(5):747-765. PubMed ID: 37461426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India's Role at the WTO Platform.
    Chattu VK; Singh B; Kaur J; Jakovljevic M
    Biomed Res Int; 2021; 2021():6658070. PubMed ID: 34485525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advancing African Medicines Agency through Global Health Diplomacy for an Equitable Pan-African Universal Health Coverage: A Scoping Review.
    Chattu VK; Dave VB; Reddy KS; Singh B; Sahiledengle B; Heyi DZ; Nattey C; Atlaw D; Jackson K; El-Khatib Z; Eltom AA
    Int J Environ Res Public Health; 2021 Nov; 18(22):. PubMed ID: 34831511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Global health diplomacy at the intersection of trade and health in the COVID-19 era.
    Chattu VK; Pooransingh S; Allahverdipour H
    Health Promot Perspect; 2021; 11(1):1-4. PubMed ID: 33758749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring risks of investor claims brought forth after the TRIPS waiver for COVID-19.
    Kulkarni SM; Kaur V
    Pharm Pat Anal; 2022 Nov; 11(6):165-174. PubMed ID: 36314462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines.
    Mermelstein S; Stevens H
    Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What is the impact of intellectual property rules on access to medicines? A systematic review.
    Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D
    Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The COVID-19 vaccine patent: a right without rationale.
    Althabhawi NM; Kashef Al-Ghetaa AA
    Med Humanit; 2023 Mar; 49(1):128-133. PubMed ID: 35523578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decolonising human rights: how intellectual property laws result in unequal access to the COVID-19 vaccine.
    Sekalala S; Forman L; Hodgson T; Mulumba M; Namyalo-Ganafa H; Meier BM
    BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34253631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Achieving Global Vaccine Equity: The Case for an International Pandemic Treaty.
    Jecker NS
    Yale J Biol Med; 2022 Jun; 95(2):271-280. PubMed ID: 35782474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Competing Responses to Global Inequalities in Access to COVID Vaccines: Vaccine Diplomacy and Vaccine Charity Versus Vaccine Liberty.
    Sparke M; Levy O
    Clin Infect Dis; 2022 Aug; 75(Suppl 1):S86-S92. PubMed ID: 35535787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global vaccine inequities and multilateralism amid COVID-19: Reconnaissance of Global Health Diplomacy as a panacea?
    Singh B; Kaur J; Chattu VK
    Health Promot Perspect; 2022; 12(4):315-324. PubMed ID: 36852205
    [No Abstract]   [Full Text] [Related]  

  • 40. Scaling Up the Global COVID-19 Vaccination Program: Production, Allocation, and Distribution with an Emphasis on Equity.
    Louden EM
    Yale J Biol Med; 2022 Sep; 95(3):379-387. PubMed ID: 36187418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.